Kun Han1, Chunni Liu2, Xiujuan Shi2, Xiaopang Rao2. 1. Department of Neurosurgery, Affiliated Hospital of Medical College of Qiingdao University, Qingdao 266100, China. 2. Department of Endocrinology, Chengyang People's Hospital in Qingdao, Qingdao 266109, China.
Abstract
OBJECTIVE: To observe the clinical curative effects of alprostadil combined with calcium dobesilate in type 2 diabetes patients with peripheral neuropathy. METHODS: We randomly divided 120 type 2 diabetes patients with diabetic peripheral neuropathy into two groups. The treatment group was prescribed alprostadil (10 μg, once daily) and oral calcium dobesilate (0.5 g, 3 times daily), and the control group was prescribed alprostadil (10 μg, once daily) for a total treatment duration of 2 weeks. The Michigan Diabetic Neuropathy Score (MDNS) and the Michigan Neuropathy Screening Instrument (MNSI) were used to evaluate differences between the two groups before and after treatment. RESULTS: Following 2 weeks of treatment, the total effective rate in the treatment group was significantly better than that of the control group (p<0.05) and the MDNS and MNSI scores in the treatment group were significantly lower than those in the control group (p<0.05 or p<0.01). CONCLUSION:Combined alprostadil and calcium dobesilate treatment for type 2 diabetic peripheral neuropathy showed good clinical efficacy and an improved curative effect than single alprostadil treatment.
RCT Entities:
OBJECTIVE: To observe the clinical curative effects of alprostadil combined with calcium dobesilate in type 2 diabetespatients with peripheral neuropathy. METHODS: We randomly divided 120 type 2 diabetespatients with diabetic peripheral neuropathy into two groups. The treatment group was prescribed alprostadil (10 μg, once daily) and oral calcium dobesilate (0.5 g, 3 times daily), and the control group was prescribed alprostadil (10 μg, once daily) for a total treatment duration of 2 weeks. The Michigan Diabetic Neuropathy Score (MDNS) and the Michigan Neuropathy Screening Instrument (MNSI) were used to evaluate differences between the two groups before and after treatment. RESULTS: Following 2 weeks of treatment, the total effective rate in the treatment group was significantly better than that of the control group (p<0.05) and the MDNS and MNSI scores in the treatment group were significantly lower than those in the control group (p<0.05 or p<0.01). CONCLUSION: Combined alprostadil and calcium dobesilate treatment for type 2 diabetic peripheral neuropathy showed good clinical efficacy and an improved curative effect than single alprostadil treatment.
Authors: Florence Njau; Nelli Shushakova; Heiko Schenk; Vera Christine Wulfmeyer; Robin Bollin; Jan Menne; Hermann Haller Journal: PLoS One Date: 2020-01-14 Impact factor: 3.240